AstraZeneca PLC - Ebitda

AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Ebitda" stands at 20.45 Billion United States Dollars for the trailing twelve months (TTM) period ending 06/30/2026.

AstraZeneca PLC's second quarter result of 5.01 Billion USD for the item "Ebitda" represents a decrease of -11.68 percent compared to it's first quarter result.

Also, AstraZeneca PLC's second quarter result of 5.01 Billion USD for the item "Ebitda" represents a decrease of -1.71 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's second quarter result of 20.45 Billion USD for the item "Ebitda" represents a decrease of -0.42 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 49.74 percent compared to the value the year prior.
The 1 year change in percent is 49.74.
The 3 year change in percent is 54.62.
The 5 year change in percent is 129.27.
The 10 year change in percent is 205.72.

The Serie's long term average value is 9.66 Billion United States Dollars. It's latest available value, on 06/30/2026, is 111.76 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 09/30/2018, to it's latest available value, on 06/30/2026, is +221.95%.
The Serie's change in percent from it's maximum value, on 03/31/2026, to it's latest available value, on 06/30/2026, is -0.424%.